Innoscience America, Inc. et al. v. Infineon Technologies North America Corp

Innoscience America, Inc. and its affiliates, Innoscience (Zhuhai) Technology Company, Ltd. and Innoscience (Suzhou) Technology Holding Company, Ltd. (collectively, "Innoscience"), initiated an Inter Partes Review (IPR) against Infineon Technologies North America Corp. ("Infineon") challenging the validity of U.S. Patent No. 8,264,003. Innoscience is a global leader and operating company specializing in gallium nitride (GaN) power devices, and is currently the world's largest producer of GaN-on-silicon wafers. Infineon, a German-based semiconductor manufacturing operating company, is a prominent player in power semiconductors, including GaN technology, used across automotive, industrial, and multi-market sectors.

This IPR is part of a broader, multi-jurisdictional "gallium nitride patent war" between the two companies, with the underlying dispute centered on alleged infringement of patents related to GaN power semiconductor devices. The specific patent challenged, US8264003, generally pertains to a power semiconductor device and its fabrication method, focusing on aspects like a lateral trench in the drift region.

The proceeding is taking place at the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) under case number IPR2025-00094, filed on February 4, 2025. The IPR has been instituted, meaning the PTAB has determined there is a reasonable likelihood that at least one claim of the patent is unpatentable. This venue is critical for challenging patent validity as it offers a streamlined and often faster alternative to district court litigation, focusing on prior art challenges to patentability. The case is notable for its involvement of two major operating companies in the rapidly expanding GaN semiconductor market, a technology essential for high-efficiency power systems in renewable energy, AI data centers, and electric vehicles. The patent dispute extends beyond the PTAB, with parallel infringement litigation ongoing in the U.S. International Trade Commission (ITC), the Northern District of California, Germany, and China, with recent rulings favoring both parties in different jurisdictions. For instance, the ITC affirmed in May 2026 that Innoscience infringed an Infineon GaN patent, leading to import and sales bans subject to presidential review, while China's Supreme People's Court upheld an injunction against Infineon in June 2026, barring sales of certain GaN products in mainland China due to infringement of Innoscience's patents.

Key Legal Developments and Outcome for IPR2025-00094

This Inter Partes Review (IPR) proceeding, IPR2025-00094, was initiated by Innoscience America, Inc., Innoscience (Zhuhai) Technology Company, Ltd., and Innoscience (Suzhou) Technology Holding Company, Ltd. (collectively "Innoscience" or "Petitioner") against Infineon Technologies North America Corp. ("Infineon" or "Patent Owner") challenging the validity of U.S. Patent No. 8,264,003 ("the '003 patent").

Chronological Legal Developments:

• 2024-03-13: Infineon Technologies initiated a patent infringement lawsuit against Innoscience (Zhuhai) Technology Company, Ltd. and Innoscience America, Inc. and its affiliates in the U.S. District Court for the Northern District of California (Case No. 4:24-cv-01553). The initial complaint asserted the '003 patent, among others, relating to gallium nitride (GaN) power semiconductor technology.
• 2024-06-12: A District Court in Munich, Germany, issued a preliminary injunction against Innoscience after Infineon filed a corresponding lawsuit, compelling Innoscience to remove infringing products from its booth at the PCIM Europe trade show.
• 2024-07-23: Infineon expanded its U.S. lawsuit, adding claims against Innoscience (Zhuhai) Technology Company, Ltd. and amending the complaint to assert a total of four patents, including the '003 patent, US8686562B2, US9899481B2, and US9070755B2.
• 2024-08-30: The U.S. District Court for the Northern District of California administratively closed (stayed) the district court case, Infineon Technologies AG et al. v. Innoscience (Suzhou) Technology Co., Ltd. et al. (Case No. 4:24-cv-01553), following the U.S. International Trade Commission's (ITC) institution of a parallel Section 337 investigation covering the same patents, including the '003 patent.
• 2025-02-04: Innoscience filed the petition for Inter Partes Review, IPR2025-00094, challenging the validity of U.S. Patent No. 8,264,003.
• 2025-05-05: In the ongoing ITC investigation, Infineon reportedly withdrew a second of its four asserted patents against Innoscience. While the specific patent is not identified as the '003 patent, this indicates a narrowing of the scope of the ITC investigation.
• 2025-07-09: The Patent Trial and Appeal Board (PTAB) issued a Scheduling Order (Paper 10) in IPR2025-00094, indicating that the IPR was instituted and outlining the subsequent due dates for filings, including the Patent Owner Response and Petitioner's Reply. The panel of Administrative Patent Judges for this IPR includes Jo-Anne M. Kokoski, Christopher M. Kaiser, and Lisa A. Murray. The institution decision would have included the Board's initial claim construction for the challenged claims of the '003 patent. Patent Owner had the option to file a preliminary response to the petition before institution, arguing against institution under 35 U.S.C. § 314. Given the institution, any arguments for discretionary denial, such as those related to "settled expectations" which were a notable consideration in other IPRs around this time for older patents, were not successful in preventing institution in this specific IPR. The '003 patent was issued in 2012, making it over 10 years old at the time of institution.
• 2025-08-01: The District Court Munich, Germany, ruled in favor of Infineon in a first-instance patent infringement case, finding that Innoscience had infringed an Infineon patent through its GaN products and prohibiting their manufacture, sale, or marketing in Germany, while also requiring Innoscience to pay damages.
• 2025-12-02: The ITC Administrative Law Judge (ALJ) issued a final initial determination (FID) in the Section 337 investigation. The FID found a violation of Section 337 by Innoscience with respect to Infineon's '481 patent, but no violation with respect to the '755 patent. The '003 patent was not among the patents for which an infringement finding was made in the FID, suggesting it was either no longer asserted or found not infringed/invalid.
• 2025-12-15: Innoscience filed a petition for review of the ITC's FID concerning the '481 patent, while Infineon filed a petition for review of the finding of no violation for the '755 patent.
• 2026-05-07: The Full Commission of the U.S. International Trade Commission affirmed the initial determination from December 2025 that Innoscience infringed Infineon's '481 patent and issued import and sales bans against Innoscience for infringing products. However, the Commission also affirmed the ALJ's finding of no violation for the '755 patent and confirmed that Innoscience's redesigned products fell outside the scope of the '481 patent. The '003 patent was not specified in the final ITC findings as a patent for which infringement was found.
• 2026-06-15: The Supreme People's Court of China issued a final review decision upholding a prior judgment from May 27, 2026, by the Suzhou Intermediate People's Court. This ruling found Infineon had infringed two of Innoscience's GaN technology patents and prohibited Infineon from selling its relevant GaN products in mainland China, also awarding Innoscience approximately US$1.38 million in damages.

Current Posture (as of 2026-06-16) for IPR2025-00094:

The IPR was instituted on July 9, 2025. Based on the typical IPR timeline, which aims for a Final Written Decision within 12 months of institution (extendable for good cause), the Final Written Decision in IPR2025-00094 would be due around July 9, 2026, or shortly thereafter if extensions were granted. As of the current date, no Final Written Decision has been publicly reported in the provided search results. Therefore, the IPR is active and likely in the post-institution briefing phase, possibly awaiting an oral hearing or approaching the deadline for the Final Written Decision.

Outcome for IPR2025-00094:

As of the current date, there is no publicly available Final Written Decision for IPR2025-00094. Therefore, the ultimate outcome regarding the patentability of the challenged claims of U.S. Patent No. 8,264,003 is pending.

Based on available public information, identifying the precise counsel of record for IPR2025-00094 directly from a specific docket entry or petition for this particular case has not been possible through the conducted web searches. Filings for IPRs at the Patent Trial and Appeal Board (PTAB) typically list the counsel of record within the petition or subsequent notices.

However, Innoscience America, Inc. and its affiliates are consistently represented by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (Finnegan) in numerous related patent disputes against Infineon and other entities, including other Inter Partes Reviews and U.S. International Trade Commission (ITC) investigations. It is highly probable that Finnegan is also representing Innoscience in IPR2025-00094.

While specific counsel for IPR2025-00094 could not be definitively named, prominent attorneys from Finnegan who have served as lead counsel for Innoscience in closely related patent litigation include:

• Lionel Lavenue - Partner and Lead Counsel.
  • Firm: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington, DC.
  • Relevant Experience: Mr. Lavenue is noted for achieving significant victories for Innoscience in high-profile patent disputes, including at the U.S. International Trade Commission, where he was identified as lead counsel.
• Chen Zang, Ph.D. - Partner and Lead Counsel.
  • Firm: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Office location is not explicitly stated for Zang in relation to Innoscience in the provided snippets, but Finnegan has offices in various locations including Washington, DC, and Palo Alto.
  • Relevant Experience: Dr. Zang has been noted for her role in Finnegan's defense strategy for Innoscience, including defeating infringement theories and invalidating patent claims at the ITC.

It is common for lead and backup counsel from the same firm to be designated for IPR proceedings. For example, in a different IPR (IPR2025-00820), Charles Collins-Chase, Luke McCammon, Melanie Magdun, and Kyle Howarth from Finnegan were listed as lead and back-up counsel.

Without direct access to the docket for IPR2025-00094, the specific roles and office locations for each attorney directly assigned to this IPR cannot be precisely confirmed.

Infineon Technologies North America Corp., the defendant and Patent Owner in IPR2025-00094, is generally represented in patent matters, including Inter Partes Review (IPR) proceedings, by Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Finnegan is a leading intellectual property law firm with a strong focus on patent litigation and post-grant review proceedings before the Patent Trial and Appeal Board (PTAB).

While Finnegan is highly likely the firm representing Infineon in this IPR, specific attorneys of record for IPR2025-00094 were not explicitly named in the publicly available search results. The "Scheduling Order" for IPR2025-00094 identifies Infineon Technologies Americas Corp. as the Patent Owner but does not list specific counsel.

Finnegan has multiple offices globally, including in Washington, D.C., Atlanta, Boston, Palo Alto, and Reston in the United States, which handle a full range of intellectual property services, including patent counseling, prosecution, and litigation. The firm is known for its extensive experience with PTAB challenges and defending patents, particularly for clients in technology sectors such as semiconductors.